中晚期食管癌98例同步放化疗的疗效观察  

Clinical Research of Chemoradiotherapy for 98 Cases Advanced Esophasead Cancer

作　　者：施哈日巴拉 侯斯琴高娃[1] 王大鹏[1] 施晓辉[2] 

机构地区：[1]内蒙古民族大学附属医院肿瘤科,028000 [2]内蒙古自治区医院外科,010000

出　　处：《实用癌症杂志》2011年第5期475-476,485,共3页The Practical Journal of Cancer

摘　　要：目的探讨同期放化疗对中晚期食管癌的疗效。方法 98例食管癌中43例行单纯放射治疗(单放组),以6 MVX常规照射,2 Gy/次,5次/周,照射总剂量为50 Gy,另55例行化放疗联合治疗(化放组),予顺铂(DDP)联合氟尿嘧啶(5-Fu)(DDP 20 mg/m2,d1～d5;5-Fu 500 mg/m2,d1～d5),28天为1个周期,放疗方案同单放组,观察两组的近期疗效、远期疗效和不良反应。结果化放组有效率(RR)为65.4%,高于单放组(44.1%)(P<0.05)。KPS评分化放组较单放组显著提高(P<0.05),化放组3年生存率为11.9%,高于单放组(6.9%)(P<0.05)。两组主要不良反应包括白细胞减少、消化道反应和放射性食管炎,化放组白细胞减少发生率高于单放组(P<0.05)。结论对中晚期食管癌患者,同期放化疗较单纯放疗的近期疗效更好,可明显改善患者的生存质量,延长患者生存时间,且相对安全。Objective To evaluate the effects of chemoradiotherapy for esophaseal cancer.Methods Of the 98 patients with advanced esophageal cancer,43 patients were treated by conformal radiotherapy alone with a total dose of 50 Gy in conventional fractionation,and 55 patients received the same radiotherapy combined with chemotherapy consisting cisplatin 20 mg/m2 d1~d5,5-Fu 500 mg/m2 d1~d5,repeated after 28 days.Results The KPS scores were significant higher in patients treated by combined chemoradiotherapy.The 3-year survival in the chemotherapy group was 17.9%,which was significantly higher than that in the radiotherapy alone group.Conclusion Chemoradiotherapy can improve the quality of life and prolong the survival time for patients with advanced esophageal cancer.

关 键 词：食管癌 同步放化疗 单纯放疗 生存率 

分 类 号：R735.1[医药卫生—肿瘤]